CEU 2018 Session Recordings
CEU 2018 Session Recordings
Keep your endocrine practice up-to-date with Clinical Endocrinology Update (CEU) Session Recordings. This activity provides the latest information available in clinical endocrinology. Taught by expert faculty in a dynamic meeting format, you will finish viewing the CEU Session Recordings confident that your endocrine practice benefits from the most current and advanced information possible. Purchase access to the CEU 2018 Session Recordings today!
To purchase access to the CEU 2018 Session Recordings activity, visit the Endocrine Society Online Store by clicking the button below.
Upon completion of this educational activity, learners will be better able to:
- Discuss state-of-the-art research in endocrinology
- Demonstrate updated knowledge of the pathophysiology, diagnosis, and treatment of diabetes, obesity, cardiovascular disease, dyslipidemia, as well as adrenal, metabolic, bone, pediatric, pituitary, thyroid, and reproductive endocrine disorders
- Employ enhanced skills and practice management techniques to improve patient care
|Category||Session Title||Featured Speaker||Session Duration|
|Adrenal||MTP #12: Adrenal Imaging||Richard Auchus MD, PhD||0:45|
|Adrenal||Congenital Adrenal Hyperplasia: Diagnosis and Treatment||Richard Auchus MD, PhD||0:30|
|Adrenal||Adrenal Fatigue and Failure: Fantasy and Facts||James Findling MD||0:30|
|Adrenal||Adrenal Case Presentations||Janet Schlechte MD||0:30|
|Adrenal||Q&A/Panel Discussion||Janet Schlechte MD||0:20|
|Adrenal||MTP #10: Updates in Pheochromocytoma and Paraganglioma||Anand Vaidya MD MMSc||0:45|
|Bone and Calcium||Treatment Goals in Osteoporosis: Is No Fracture the Only Marker of Success||Carolyn Becker MD||0:30|
|Bone and Calcium||MTP #1: New Enhancements to DXA and FRAX: A Case-based Approach||Carolyn Becker MD||0:45|
|Bone and Calcium||Hypophosphatemic Disorders and their Management||Suzanne Jan de Beur MD||0:30|
|Bone and Calcium||Q&A/Panel Discussion||Suzanne Jan de Beur MD||0:15|
|Bone and Calcium||Osteoporosis: Answers to Patients’ Questions||Ann Kearns MD, PhD||0:30|
|Calcium and Bone||Update on the Management of Renal Bone Disease||Robert Wermers MD||0:30|
|Calcium and Bone||MTP #2: Clinical Pearls in Hypercalcemia||Robert Wermers MD||0:45|
|Cardiovascular Endocrinology||Diabetes and Heart Failure||Matthew Cavender MD, MPH||0:30|
|Cardiovascular Endocrinology||Q&A/Panel Discussion||Matthew Cavender MD, MPH||0:15|
|Cardiovascular Endocrinology||Using New and Emerging Therapies in Managing of Hypercholesterolemia||Ira Goldberg MD||0:30|
|Cardiovascular Endocrinology||MTP #4: Risk Stratification: Coronary Calcium, ApoB, LDL Particle Size, Lp(a). Which Ones are Worthwhile and Why?||Ira Goldberg MD||0:45|
|Diabetes||What’s New in Continuous Glucose Monitoring?||Anders Carlson MD||0:30|
|Diabetes||Renal Outcomes and New Diabetes Medications||Mark Molitch MD||0:45|
|Diabetes||MTP #11: A New Era for Diabetic Ketoacidosis||Mark Molitch MD||0:45|
|Diabetes||Diabete$: Patient$, Doctor$, Insurer$, Manufacturer$, and $ociety||Alvin Powers MD||0:30|
|Diabetes||MTP #9: Beta-Cell Replacement Therapy for Type 1 Diabetes||Michael Rickels MD||0:45|
|Diabetes||MTP #8: Update on Diabetic Retinopathy||Sharon Solomon MD||0:45|
|Diabetes||What’s Next after Basal Insulin||Carol Wysham MD||0:30|
|Diabetes||MTP #7: How I Use Concentrated Insulins||Carol Wysham MD||0:45|
|Female Repro||Menopausal Hormone Therapy and Alternatives||Margaret Wierman MD||0:30|
|Female Repro||Q&A/Panel Discussion||Margaret Wierman MD||0:20|
|Female Repro||Hyperandrogenic Anovulation: PCOS and Tumors||Margaret Wierman MD||0:30|
|Female Repro||Q&A/Panel Discussion||Margaret Wierman MD||0:15|
|Transgender Medicine||MTP #5: Transgender Women: Evaluation and Management||Joshua Safer MD||0:45|
|Male reproduction||MTP #6: Testosterone Replacement Cases||Bradley Anawalt MD||0:45|
|Male reproduction||Cased-based Debate of Whether to Start Testosterone Therapy and How to Monitor||Bradley Anawalt MD||0:30|
|Male reproduction||Pros and Cons with Non-Insulin Therapies in Gestational Diabetes||Linda Barbour MD, MSPH||0:30|
|Male reproduction||Q&A/Panel Discussion||Linda Barbour MD, MSPH||0:15|
|Male reproduction||Obesity-Related Low Testosterone||Shehzad Basaria MD, MBBS||0:30|
|Neuroendocrine and Pituitary||Treatment of Cushing Disease when Surgery Fails: Individualized Case-based Approach||James Findling MD||0:30|
|Neuroendocrine and Pituitary||Treatment with Anti-PD-1/PD-L1 and Anti-CTLA-4 Drugs: Endocrine Side Effects||Maria Fleseriu MD||0:30|
|Neuroendocrine and Pituitary||MTP #14: Management of Women with Hypopituitarism to Conceive and During Pregnancy||Maria Fleseriu MD||0:45|
|Neuroendocrine and Pituitary||Medical Treatment of Acromegaly: A Stepwise Approach||Shlomo Melmed MD||0:30|
|Neuroendocrine and Pituitary||Q&A/Panel Discussion||Shlomo Melmed MD||0:15|
|Neuroendocrine and Pituitary||MTP #13: Imaging-based Differential Diagnosis and Management of Pituitary Masses||Shlomo Melmed MD||0:45|
|Obesity||Pharmacotherapy for Obesity||Marc-Andre Cornier MD||0:30|
|Obesity||MTP #3: What’s New in Weight Loss Diets?||Marc-Andre Cornier MD||0:45|
|Obesity||Management of the Patient Before and After Bariatric Surgery||Christopher Still DO||0:30|
|Obesity||Q&A/Panel Discussion||Christopher Still DO||0:15|
|Thyroid||MTP #16: Indications and Consequences of High-Dose LT4 Therapy||Kristien Boelaert MD, PhD||0:45|
|Thyroid||Subclinical Thyroid Disorders||Kristien Boelaert MD, PhD||0:30|
|Thyroid||Q&A/Panel Discussion||Kristien Boelaert MD, PhD||0:15|
|Thyroid||Challenging Thyroid Cases with Faculty Panel||Kristien Boelaert MD, PhD||0:45|
|Thyroid||MTP #15: NIFTP||Thomas Giordano MD, PhD||0:45|
|Thyroid||Papillary Thyroid Microcarcinomas||Megan Haymart MD||0:30|
|Thyroid||Overview of Thyroid Nodules||Susan Mandel MD, MPH||0:30|
The faculty, committee members, and staff who are in position to control the content of this activity are required to disclose to The Endocrine Society and to learners any relevant financial relationship(s) of the individual or spouse/partner that have occurred within the last 12 months with any commercial interest(s) whose products or services are related to the CME content. Financial relationships are defined by remuneration in any amount from the commercial interest(s) in the form of grants; research support; consulting fees; salary; ownership interest (e.g., stocks, stock options, or ownership interest excluding diversified mutual funds); honoraria or other payments for participation in speakers' bureaus, advisory boards, or boards of directors; or other financial benefits. The intent of this disclosure is not to prevent CME planners with relevant financial relationships from planning or delivery of content, but rather to provide learners with information that allows them to make their own judgments of whether these financial relationships may have influenced the educational activity with regard to exposition or conclusion.
The Endocrine Society has reviewed all disclosures and resolved or managed all identified conflicts of interest, as applicable.
|To view disclosure information for all CEU presenters, please view the full Disclaimers and Disclosures page here|
The information presented in this activity represents the opinion of the faculty and is not necessarily the official position of the Endocrine Society.
USE OF PROFESSIONAL JUDGMENT:
The educational content in this self-assessment test relates to basic principles of diagnosis and therapy and does not substitute for individual patient assessment based on the health care provider’s examination of the patient and consideration of laboratory data and other factors unique to the patient. Standards in medicine change as new data become available.
DRUGS AND DOSAGES:
When prescribing medications, the physician is advised to check the product information sheet accompanying each drug to verify conditions of use and to identify any changes in drug dosage schedule or contraindications.
PRIVACY AND CONFIDENTIALITY STATEMENT
The Endocrine Society will record learner’s personal information as provided on CME evaluations to allow for issuance and tracking of CME certificates. The Endocrine Society may also track aggregate responses to questions in activities and evaluations and use these data to inform the ongoing evaluation and improvement of its CME program. No individual performance data or any other personal information collected from evaluations will be shared with third parties.
ACKNOWLEDGMENT OF COMMERCIAL SUPPORT
The Endocrine Society is proud to partner with industry to advance excellence and promote scientific discovery, medical practice and human health.:
The Endocrine Society is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The Endocrine Society has achieved Accreditation with Commendation.The Endocrine Society designates this enduring activity for a maximum of 28.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Check the boxes corresponding to the Session Recording topical courses in which you would like to enroll, then click the Enroll button.
If you are already enrolled, click the name of the topical course to go to that course.